Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +11.41%
#3 Meteora Meteora +10.48%
#4 Unit Pump Unit Pump +10.28%
#5 Pump.fun Pump.fun +10.28%
#6 eCash eCash +8.55%
#7 OPENLOOT OPENLOOT +8.41%
#8 Glidr Glidr +6.76%
#9 Ergo Ergo +6.51%
#10 Qkacoin Qkacoin +6.46%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rank in Stocks #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Share Price
$0.55
Last synced: 2025-02-11
Market Cap
$28.90M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Marinus Pharmaceuticals, Inc. (MRNS)

Category

Healthcare
Number of shares outstanding for Marinus Pharmaceuticals, Inc. (MRNS)
Number of shares outstanding as of September 2024: 57.23M
According to Marinus Pharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 57.23M. At the end of December 2022 the company had 39.07M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Marinus Pharmaceuticals, Inc. (MRNS) from 2012 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 57.23M 6.48%
2023 53.75M 37.56%
2022 39.07M 6.47%
2021 36.70M 34.57%
2020 27.27M 100.10%
2019 13.63M 33.30%
2018 10.22M 73.72%
2017 5.89M 20.73%
2016 4.87M 30.69%
2015 3.73M 142.49%
2014 1.54M -23.70%
2013 2.02M 0.00%
2012 2.02M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 343.65%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 591.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M 8.66%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 744.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH